BioSpectator Reporter Jeongmin Jo
Combining 干细胞 application technology and pain control technology to jointly develop treatments for major spinal diseases including degenerative disc disease and spinal cord injury
CHA University 盆唐CHA医院 announced on the 18th that it has signed a business agreement with RudaCure, a company developing treatments for 神经性疼痛, for the 'development of spinal disease regenerative therapeutics.'
Based on this agreement, 盆唐CHA医院 and RudaCure will combine 盆唐CHA医院's 干细胞 application regenerative technology with RudaCure's pain control technology to pursue: ▲ development of new spinal disease treatments with pain control and regenerative effects ▲ conducting 临床试验 of jointly developed treatments at 盆唐CHA医院 ▲ new drug approval based on joint 临床试验 ▲ joint 技术转让 and 新药开发 for industrialization of spinal disease treatments.
Jaehua Kim, Director of 盆唐CHA医院, stated, "Through this agreement between 盆唐CHA医院, which has strengths in 干细胞 research for major spinal diseases such as degenerative disc disease and spinal cord injury, and RudaCure, which specializes in 疼痛治疗药 新药开发, we look forward to creating cases of innovative treatment technology for spinal diseases."